Based on Your Reading:
Get Your Free Mesothelioma Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Mesothelin is a protein made by mesothelial cells that line the pleura, peritoneum and pericardium. The antigen is produced at higher levels when the cells turn cancerous. Blood tests to measure mesothelin help monitor mesothelioma growth and response to treatment.
Written by Karen Selby, RN | Medically Reviewed By Dr. Rupesh Kotecha | Edited By Walter Pacheco | Last Update: November 18, 2024
Mesothelin is a protein found on the surface of mesothelial cells. Researchers suspect that the mesothelin protein plays a role in cell adhesion. This process allows cells to interact with and attach to neighboring cells.
Studies suggest that an interaction between mesothelin and a protein called MUC16 or CA125 may promote the spread of peritoneal mesothelioma tumors by cell adhesion.
Mesothelin can be over-expressed (over-produced) by several cancers, including malignant mesothelioma, ovarian cancer and pancreatic adenocarcinoma.
This factor makes mesothelin a good candidate as a tumor marker to diagnose and track mesothelioma. It’s also a good target for anti-cancer therapy.
Tracking Mesothelin Throughout Treatment
As mesothelioma tumors grow, they produce more mesothelin. When tumors shrink, they produce less mesothelin. Measuring mesothelin allows doctors to monitor the growth of mesothelioma and its response to treatment.
A 2006 study published in Clinical Cancer Research reported a 71% decrease in mesothelin levels the day after cytoreductive surgery among peritoneal mesothelioma patients. Mesothelin became undetectable by the seventh day after surgery. This research suggests that mesothelin can help doctors monitor a patient’s response to treatment.
The big hope with mesothelin is that it will prove an effective target for anti-cancer therapy among people with mesothelioma.
Healthy mesothelial cells express mesothelin. That expression increases when the cells become cancerous. Mesothelin expression is high in epithelial mesothelioma tumors but not in sarcomatoid tumors. This limitation means mesothelin does not help diagnose, monitor or treat sarcomatoid mesothelioma.
Doctors have tried to develop a mesothelin cancer test, but it hasn’t proven successful as a diagnostic tool. However, it is helpful when combined with other diagnostic tests to confirm a mesothelioma diagnosis.
Doctors use a mesothelin ELISA test to measure mesothelin levels in a person’s blood. ELISA stands for enzyme-linked immunosorbent assay, and it uses antibodies and color change to identify substances.
These tests help doctors diagnose cancer and monitor its growth or response to treatment. Several blood tests measure mesothelin through soluble mesothelin-related peptides (SMRP), which are soluble molecules related to the mesothelin family of proteins.
MESOMARK and the N-ERC/mesothelin test are the most well-known tests. In 2007, the FDA approved MESOMARK as a tool to monitor mesothelioma but not a diagnostic tool.
MESOMARK and N-ERC/mesothelin cannot diagnose mesothelioma on their own. However, researchers are hopeful that combining a mesothelin test with tests that measure other biomarkers, such as calretinin, will improve mesothelioma detection. Another mesothelin blood test is under review at the University of Bristol in the United Kingdom.
Get Your Free Mesothelioma Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Primary drugs that target mesothelin are part of a class of drugs called antibodies. The immunotherapy drug Amatuximab (MORab-009) targets mesothelin.
The immune system creates antibodies, proteins that hunt down things that cause harm, such as viruses, bacteria and cancer cells. These harmful agents have proteins called antigens that antibodies attach to, like a lock and key.
Mesothelin is an antigen, and the drugs that target it are antibodies.
Approximately 40% of mesothelioma patients’ immune systems generate anti-mesothelin antibodies. They attach to and attack mesothelin-bearing cells.
Researchers are working to identify anti-mesothelin antibodies to use as anti-cancer therapies. They have identified several and tested them in clinical trials without significant success.
Other types of anti-mesothelin drugs include CRS-207, which is a cancer vaccine that uses a modified form of the Listeria bacterium to target mesothelin. A person’s own immune cells, called CAR T cells, and the microRNA molecule miR-21-5p also target mesothelin.
Mesothelin exists in both healthy and cancerous mesothelial cells, making it tricky to use it as a therapeutic target.
There is a lot of research on anti-mesothelin antibodies. No available options have proven effective enough to be approved by the U.S. Food and Drug Administration (FDA).
But some of them have helped a handful of people with mesothelioma far outlive their prognosis.
For example, Andy Ashcroft lived for years with stage 4 pleural mesothelioma thanks to joining a clinical trial that tested Amatuximab, an anti-mesothelin antibody.
Ashcroft was among the few mesothelioma participants who responded to the drug. The trial ended because so few mesothelioma patients responded the way Ashcroft did.
Researchers are working on finding new anti-cancer agents that may one day work as an anti-cancer therapy for mesothelioma. A 2017 study identified a molecule called miR-21-5p that may block mesothelioma from spreading by targeting mesothelin.
A 2015 study in the journal Nature identified new antibodies, called YP218 and YP223, that target mesothelin. Extensive research is necessary to determine whether these new antibodies will prove successful.
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
Selby, K. (2024, November 18). Mesothelin Expression in Mesothelioma. Asbestos.com. Retrieved November 21, 2024, from https://www.asbestos.com/mesothelioma/mesothelin/
Selby, Karen. "Mesothelin Expression in Mesothelioma." Asbestos.com, 18 Nov 2024, https://www.asbestos.com/mesothelioma/mesothelin/.
Selby, Karen. "Mesothelin Expression in Mesothelioma." Asbestos.com. Last modified November 18, 2024. https://www.asbestos.com/mesothelioma/mesothelin/.
A medical doctor who specializes in mesothelioma or cancer treatment reviewed the content on this page to ensure it meets current medical standards and accuracy.
Please read our editorial guidelines to learn more about our content creation and review process.
Dr. Rupesh Kotecha is a renowned radiation oncologist in leadership roles at Miami Cancer Institute. He is an associate professor at Florida International University's college of medicine and an adjunct faculty member at Memorial Sloan Kettering.
Mesothelioma Center - Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.